Cardiogenic shock
disease diseaseOn this page
Summary
Cardiogenic shock (MONDO:0800175) is a disease and 220 clinical trials. Top therapeutic interventions include cangrelor, dobutamine, and dopamine. A subtype of heart disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 30
- Clinical trials: 220
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 40 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
30 HPO clinical features (Orphanet curated; top 30 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002615 | Hypotension | Very frequent (80-99%) |
| HP:0003115 | Abnormal EKG | Very frequent (80-99%) |
| HP:0005162 | Abnormal left ventricular function | Very frequent (80-99%) |
| HP:0009805 | Low-output congestive heart failure | Very frequent (80-99%) |
| HP:0000961 | Cyanosis | Frequent (30-79%) |
| HP:0000969 | Edema | Frequent (30-79%) |
| HP:0001635 | Congestive heart failure | Frequent (30-79%) |
| HP:0001658 | Myocardial infarction | Frequent (30-79%) |
| HP:0001695 | Cardiac arrest | Frequent (30-79%) |
| HP:0002094 | Dyspnea | Frequent (30-79%) |
| HP:0004372 | Reduced consciousness/confusion | Frequent (30-79%) |
| HP:0006670 | Impaired myocardial contractility | Frequent (30-79%) |
| HP:0011675 | Arrhythmia | Frequent (30-79%) |
| HP:0012418 | Hypoxemia | Frequent (30-79%) |
| HP:0012764 | Orthopnea | Frequent (30-79%) |
| HP:0030830 | Crackles | Frequent (30-79%) |
| HP:0030848 | Elevated jugular venous pressure | Frequent (30-79%) |
| HP:0030851 | Low pulse pressure | Frequent (30-79%) |
| HP:0030876 | Increased pulmonary capillary wedge pressure | Frequent (30-79%) |
| HP:0100520 | Oliguria | Frequent (30-79%) |
| HP:0001289 | Confusion | Occasional (5-29%) |
| HP:0001653 | Mitral regurgitation | Occasional (5-29%) |
| HP:0001942 | Metabolic acidosis | Occasional (5-29%) |
| HP:0002151 | Increased circulating lactate concentration | Occasional (5-29%) |
| HP:0002240 | Hepatomegaly | Occasional (5-29%) |
| HP:0002321 | Vertigo | Occasional (5-29%) |
| HP:0003259 | Elevated circulating creatinine concentration | Occasional (5-29%) |
| HP:0012251 | ST segment elevation | Occasional (5-29%) |
| HP:0001259 | Coma | Very rare (<1-4%) |
| HP:0001708 | Right ventricular failure | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cardiogenic shock |
| Mondo ID | MONDO:0800175 |
| Orphanet | 97292 |
| ICD-10-CM | R57.0 |
| ICD-11 | 1974956233 |
| UMLS | C0036980 |
| MedGen | 48650 |
| GARD | 0019362 |
| MedDRA | 10007625 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of heart disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › cardiogenic shock
Related subtypes (33): endocardium disorder, pericardium disorder, cardiac tuberculosis, heart conduction disease, hypertensive heart disease, heart valve disorder, cardiomyopathy, coronary artery disorder, heart failure, congenital heart disease, heart aneurysm, rheumatic heart disease, cardiac rhythm disease, white forelock with malformations, atrioventricular defect-blepharophimosis-radial and anal defect syndrome, microcephaly-cardiac defect-lung malsegmentation syndrome, PHACE syndrome, microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type, cardiac anomalies-heterotaxy syndrome, polyvalvular heart disease syndrome, Thomas syndrome, 22q11.2 deletion syndrome, myocardial rupture, heart neoplasm, aortopulmonary window, cor biloculare, inflammation of heart layer, myocardial disorder, carcinoid heart disease, omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome, coronary microvascular disorder, cardiac ventricle disorder, cardiogenetic disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 220.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 182 |
| PHASE4 | 15 |
| PHASE2 | 9 |
| PHASE3 | 7 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05168462 | PHASE4 | RECRUITING | Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction |
| NCT05527717 | PHASE4 | RECRUITING | Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator |
| NCT06696235 | PHASE4 | RECRUITING | Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator |
| NCT07527156 | PHASE4 | RECRUITING | Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure |
| NCT00324766 | PHASE4 | COMPLETED | Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. |
| NCT01367743 | PHASE4 | COMPLETED | Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock |
| NCT01927549 | PHASE4 | COMPLETED | Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock |
| NCT02544594 | PHASE4 | COMPLETED | Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction |
| NCT03207165 | PHASE4 | COMPLETED | Milrinone Versus Dobutamine in Critically Ill Patients |
| NCT03387605 | PHASE4 | UNKNOWN | Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine |
| NCT03437369 | PHASE4 | UNKNOWN | Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock |
| NCT03549923 | PHASE4 | COMPLETED | Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE) |
| NCT03551964 | PHASE4 | COMPLETED | Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction |
| NCT04206865 | PHASE4 | WITHDRAWN | Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output |
| NCT04369573 | PHASE4 | TERMINATED | Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock |
| NCT04020263 | PHASE3 | RECRUITING | Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock |
| NCT05879276 | PHASE3 | RECRUITING | Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. |
| NCT07583446 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock |
| NCT00093301 | PHASE2/PHASE3 | UNKNOWN | Levosimendan Versus Dobutamine in Shock Patients |
| NCT03340779 | PHASE3 | UNKNOWN | Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock |
| NCT03773822 | PHASE3 | COMPLETED | Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. |
| NCT03989531 | PHASE2/PHASE3 | COMPLETED | Adrecizumab in Cardiogenic Shock |
| NCT04728932 | PHASE3 | COMPLETED | LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients |
| NCT04990349 | PHASE3 | COMPLETED | Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock |
| NCT05594342 | PHASE3 | UNKNOWN | Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support |
| NCT05350592 | PHASE2 | ACTIVE_NOT_RECRUITING | Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock |
| NCT05975021 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C |
| NCT06080074 | PHASE2 | RECRUITING | Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System |
| NCT06336655 | PHASE2 | RECRUITING | Physiology of Unloading VA ECMO Trial |
| NCT06522594 | PHASE2 | RECRUITING | REMAP ECMO - Beta Receptor Modulation Trial |
| NCT06792643 | PHASE2 | RECRUITING | Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO |
| NCT07461961 | PHASE2 | NOT_YET_RECRUITING | CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock |
| NCT00445211 | PHASE2 | TERMINATED | HEROIC (Heparin Requirement in Counterpulsation) |
| NCT02591771 | PHASE2 | COMPLETED | Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock |
| NCT04325035 | PHASE2 | COMPLETED | The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock |
| NCT05699005 | PHASE1 | RECRUITING | Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO |
| NCT07380659 | PHASE1 | NOT_YET_RECRUITING | Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock |
| NCT05700617 | EARLY_PHASE1 | RECRUITING | Cardiac Power Output in Cardiogenic Shock Patients |
| NCT03313687 | Not specified | RECRUITING | SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK |
| NCT03378739 | Not specified | RECRUITING | Inova Cardiogenic Shock Registry (INOVA SHOCK) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CANGRELOR | 4 | 6 |
| DOBUTAMINE | 4 | 3 |
| DOPAMINE | 4 | 3 |
| NOREPINEPHRINE | 4 | 3 |
| ESMOLOL | 4 | 2 |
| IVABRADINE | 4 | 2 |
| BIVALIRUDIN | 4 | 1 |
| EPINEPHRINE | 4 | 1 |
| MILRINONE | 4 | 1 |
| LEVOSIMENDAN | 3 | 7 |
| ISTAROXIME | 2 | 3 |
| ENIBARCIMAB | 2 | 1 |
| RACEPINEPHRINE | 2 | 1 |
| CHEMBL3989692 | 0 | 3 |
| CHEMBL469045 | 0 | 3 |
| CHEMBL432 | 0 | 2 |